Clinical Trial

The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors

Study acronym: CAR-T
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated April 4, 2025 (before its estimated February 28, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is an open, single-arm, prospective, Phase I/II clinical study using "3+3" dose escalation and dose expansion to investigate the safety, maximum tolerated dose, in vivo pharmacokinetic profile, and preliminary efficacy of CAR-T cell injections for the treatment of relapsed/refractory malignant hematological neoplasms in subjects.
Trial Details
NCT Number NCT06911710
Lead Sponsor Tianjin Medical University General Hospital
Collaborators: Hebei Taihe Chunyu Biotechnology Co., Ltd
Conditions Lymphoma, B-cell, Aggressive Non-Hodgkin (B-NHL), AML (Acute Myelogenous Leukemia), Myeloma Multiple, B-ALL, T-ALL/Lymphoma, T-lymphocyte Lymphoma
Enrollment 90 participants
Start Date 2024-11-09
Primary Completion 2026-02-28 (estimated)
Study Completion 2027-02-28 (estimated)
Updated on ClinicalTrials.gov 2025-04-04